指南与共识复苏、休克与脓毒症重症综合管理与镇静镇痛

体外血液吸附治疗脓毒性休克的系统综述与专家共识:印度视角

Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective.
指南 / 共识 · World J Crit Care Med · 2024-03-09
一句话结论印度专家共识支持CytoSorb®血液吸附作为脓毒性休克的辅助治疗,并给出使用指导。

该共识由11名危重症、急诊与重症医学专家采用改良Delphi法制定,基于2011年1月至2023年3月PubMed文献的系统综述与证据评价。围绕辅助治疗需求、启动时机、白介素-6水平、治疗时长、吸附器更换、安全性、先决条件、疗效终点和管理流程图形成9条共识声明,经三轮投票全部达成共识(11/11,100%)。共识支持CytoSorb®血液吸附作为脓毒性休克的辅助治疗以改善预后,并在开放性问题中提出建立登记数据库的学会或协会的必要性。

要点

  • 11名危重症、急诊与重症医学专家经三轮改良Delphi投票,9条声明全部达成共识,投票参与率100%。
  • 共识支持CytoSorb®体外血液吸附作为脓毒性休克的辅助治疗,以改善预后。
  • 共识涵盖启动时机、白介素-6水平检测需求、治疗时长、吸附器更换、安全性、先决条件与疗效终点等9个主题。
  • 专家小组在开放性问题中认为有必要成立学会或协会,建立涵盖CytoSorb®所有适应证的登记数据库。

适用人群与场景

  • 脓毒性休克患者,作为标准治疗之外的辅助治疗场景。

处置流程与药物剂量

  • 共识声明涉及的主题包括:辅助治疗的需求、启动时机、白介素-6水平检测的需求、治疗时长、吸附器更换、安全性、先决条件、疗效终点和管理流程图。

研究设计与关键结果

  • 制定方法:在PubMed检索2011年1月至2023年3月发表的英文文献,系统综述CytoSorb®在脓毒症、脓毒性休克中的应用,结合证据评价与专家意见形成声明,采用改良Delphi法。
  • 专家组:来自危重症、急诊医学和重症医学的11名专家,对9条声明和1个开放性问题进行投票。
  • 投票过程:全部11名专家(100%)参与第一、二、三轮投票;经三轮迭代投票并调整2条声明后,9条声明全部达成共识。
  • 开放性问题(Q10)聚焦「CytoSorb®治疗的未来建议」,专家小组认为有必要成立学会或协会,建立涵盖CytoSorb®所有适应证的登记数据库。

证据类型、等级与局限

  • 证据类型:系统综述结合改良Delphi专家共识(指南/共识)。
  • 共识形成:基于文献分析识别知识缺口,结合证据评价与专家意见,经三轮迭代投票达成共识。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 该印度视角共识支持并提供指导:CytoSorb®血液吸附可作为脓毒性休克患者的辅助治疗,以取得最佳预后。
  • 专家小组认为有必要成立学会或协会,建立涵盖CytoSorb®所有适应证的登记数据库。

指南或共识出处

  • 文献来源:World J Crit Care Med;标题:Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective.
  • 检索数据库与时间范围:PubMed,2011年1月至2023年3月,英文文献。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Septic shock is a severe form of sepsis characterised by deterioration in circulatory and cellular-metabolic parameters. Despite standard therapy, the outcomes are poor. Newer adjuvant therapy, such as CytoSorb® extracorporeal haemoadsorption device, has been investigated and shown promising outcome. However, there is a lack of some guidance to make clinical decisions on the use of CytoSorb® haemoadsorption as an adjuvant therapy in septic shock in Indian Setting. Therefore, this expert consensus was formulated.

AIM: To formulate/establish specific consensus statements on the use of CytoSorb® haemoadsorption treatment based on the best available evidence and contextualised to the Indian scenario.

METHODS: We performed a comprehensive literature on CytoSorb® haemoadsorption in sepsis, septic shock in PubMed selecting papers published between January 2011 and March 2023 2021 in English language. The statements for a consensus document were developed based on the summarised literature analysis and identification of knowledge gaps. Using a modified Delphi approach combining evidence appraisal and expert opinion, the following topics related to CytoSorb® in septic shock were addressed: need for adjuvant therapy, initiation timeline, need for Interleukin -6 levels, duration of therapy, change of adsorbers, safety, prerequisite condition, efficacy endpoints and management flowchart. Eleven expert members from critical care, emergency medicine, and the intensive care participated and voted on nine statements and one open-ended question.

RESULTS: Eleven expert members from critical care, emergency medicine, and the intensive care participated and voted on nine statements and one open-ended question. All 11 experts in the consensus group (100%) participated in the first, second and third round of voting. After three iterative voting rounds and adapting two statements, consensus was achieved on nine statements out of nine statements. The consensus expert panel also recognised the necessity to form an association or society that can keep a registry regarding the use of CytoSorb® for all indications in the open-ended question (Q10) focusing on "future recommendations for CytoSorb® therapy".

CONCLUSION: This Indian perspective consensus statement supports and provides guidance on the use of CytoSorb® haemoadsorption as an adjuvant treatment in patients with septic shock to achieve optimal outcomes.

来源:World J Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mehta Y, Ansari AS, Mandal AK, et al. Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective. World J Crit Care Med. 2024. PMID: 38633478. doi:10.5492/wjccm.v13.i1.89026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。